Corbus Pharmaceuticals Holdings, Inc. - 8-K Filing
Corbus Pharmaceuticals appointed Nishant Saxena as Chief Business Officer effective May 21, 2026 under a two-year employment agreement with an annual base salary of $470,000 and equity compensation including 192,300 stock options vesting over four years and 58,300 restricted stock units vesting annually. The company also granted Brent Pfeiffenberger, newly appointed to the board, a nonqualified stock option for 24,700 shares and 7,500 restricted stock units. (Items: 1.01 Entry into a Material Definitive Agreement, 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offi, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $CRBP